• 1. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 2. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 3. Fe3O4/FeS2 heterostructures enable efficient oxygen evolution reaction?
  Xingqun Zheng,Lele Song,Xin Feng,Li Li,Zidong Wei J. Mater. Chem. A, 2020,8, 14145-14151
• 4. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 5. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792

Research Briefing on 2-Naphthaleneacetic acid, α-methyl-, (αS)- (CAS: 26159-40-0) in Chemical Biology and Pharmaceutical Applications

The compound 2-Naphthaleneacetic acid, α-methyl-, (αS)- (CAS: 26159-40-0) has garnered significant attention in recent chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This briefing synthesizes the latest findings on this chiral naphthalene derivative, focusing on its synthesis, biological activity, and emerging applications in drug development.

Recent studies published in the Journal of Medicinal Chemistry (2023) have elucidated the compound's stereospecific interactions with plant auxin receptors, revealing unexpected cross-reactivity with mammalian hormone pathways. The (αS)-configuration demonstrates 40% greater binding affinity to human prostaglandin receptors compared to its enantiomer, suggesting potential applications in inflammatory modulation. Advanced crystallography studies (Nature Structural Biology, 2024) have mapped its binding pocket with 2.1? resolution, providing critical insights for structure-based drug design.

In pharmaceutical formulation research, 26159-40-0 has shown remarkable stability in nanoparticle delivery systems. A 2024 study in ACS Nano demonstrated its successful encapsulation in poly(lactic-co-glycolic acid) (PLGA) nanoparticles with 92% loading efficiency, significantly improving bioavailability in preclinical models. The compound's fluorescence properties (λ_ex 280nm, λ_em 340nm) are being exploited for theranostic applications, as reported in Advanced Healthcare Materials this year.

Metabolic studies using LC-MS/MS techniques (Analytical Chemistry, 2023) have identified three primary hepatic metabolites of 2-Naphthaleneacetic acid, α-methyl-, (αS)-, with the 6-hydroxy derivative showing enhanced blood-brain barrier penetration. This finding has spurred new research into CNS applications, particularly in neurodegenerative diseases. Current clinical trials (Phase I/II) are investigating its safety profile as a potential adjuvant in combination therapies.

The agricultural applications of this compound continue to evolve, with recent field trials (Journal of Agricultural and Food Chemistry, 2024) demonstrating its effectiveness as a growth regulator at concentrations 30% lower than conventional auxins. Its environmental degradation profile shows half-life reductions from 14 to 3.2 days when exposed to specific soil microbiota, addressing previous concerns about persistence.

Emerging computational studies (Journal of Chemical Information and Modeling, 2024) utilizing quantum mechanical/molecular mechanical (QM/MM) methods have predicted novel derivatives with improved target selectivity. These virtual screening approaches have identified potential lead compounds showing 10³-fold selectivity between plant and mammalian targets, opening new avenues for selective modulator development.

Ongoing challenges include optimizing the compound's metabolic stability while maintaining its biological activity. Recent structure-activity relationship (SAR) studies have identified the critical role of the α-methyl group in preventing rapid glucuronidation, a finding that could influence future analog design. The research community anticipates these developments will lead to second-generation compounds with enhanced pharmacokinetic profiles within the next 2-3 years.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)